[go: up one dir, main page]

WO2001045740A3 - Compositions and methods for treatment of breast cancer - Google Patents

Compositions and methods for treatment of breast cancer Download PDF

Info

Publication number
WO2001045740A3
WO2001045740A3 PCT/US2000/035315 US0035315W WO0145740A3 WO 2001045740 A3 WO2001045740 A3 WO 2001045740A3 US 0035315 W US0035315 W US 0035315W WO 0145740 A3 WO0145740 A3 WO 0145740A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
present
subjects
methods
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/035315
Other languages
French (fr)
Other versions
WO2001045740A2 (en
Inventor
Geoffrey Clark
Joanne Zujewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to AU22928/01A priority Critical patent/AU2292801A/en
Publication of WO2001045740A2 publication Critical patent/WO2001045740A2/en
Publication of WO2001045740A3 publication Critical patent/WO2001045740A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to compositions comprising an estrogen receptor modulator and a farnesyl transferase inhibitor and methods for treating and/or preventing cancer. In particular, the present invention provides compositions and methods for the treatment and/or prevention of breast cancer. Specifically, the present invention provides combination drug therapy that acts in a synergistic manner to inhibit the growth of cancer cells (e.g., breast cells). In some embodiments of the present invention, therapeutic agents are administered to subjects suspected of having cancer or being susceptible to cancer, subjects with cancer, subjects experiencing a recurrence of cancer, or subjects who are post-operative for cancer. It is also contemplated that the treatment agents be prophylactically administered to patients at risk for development of cancer.
PCT/US2000/035315 1999-12-22 2000-12-20 Compositions and methods for treatment of breast cancer Ceased WO2001045740A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU22928/01A AU2292801A (en) 1999-12-22 2000-12-20 Compositions and methods for treatment of breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17192899P 1999-12-22 1999-12-22
US60/171,928 1999-12-22

Publications (2)

Publication Number Publication Date
WO2001045740A2 WO2001045740A2 (en) 2001-06-28
WO2001045740A3 true WO2001045740A3 (en) 2002-04-25

Family

ID=22625677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035315 Ceased WO2001045740A2 (en) 1999-12-22 2000-12-20 Compositions and methods for treatment of breast cancer

Country Status (2)

Country Link
AU (1) AU2292801A (en)
WO (1) WO2001045740A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5491681B2 (en) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Farnesyl protein transferase inhibitors for the treatment of breast cancer
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
CN113559222A (en) * 2021-09-14 2021-10-29 临沧宏胜生物科技开发有限公司 Traditional Chinese medicine composition for inhibiting breast cancer cell metastasis and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032114A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO2000025789A1 (en) * 1998-10-29 2000-05-11 Merck & Co., Inc. A method of treating endometriosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032114A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO2000025789A1 (en) * 1998-10-29 2000-05-11 Merck & Co., Inc. A method of treating endometriosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"[New strategies for therapy of breast cancer]. BRUSTKREBS: NEUE THERAPIESTRATEGIEN.", MEDIZINISCHE MONATSSCHRIFT FUR PHARMAZEUTEN, (1999) 22/7 (214-216)., XP000956081 *
MOASSER M M ET AL: "Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 FEB 17) 95 (4) 1369-74., XP002187318 *
RANGANATHAN S R ET AL: "Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 523, XP002145679, ISSN: 0197-016X *
SKRZAT S G ET AL: "Interaction of the farnesyl protein transferase inhibitor (FTI) R115777 with cytotoxic chemotherapeutics in vitro and in vivo.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 523, XP002145678, ISSN: 0197-016X *

Also Published As

Publication number Publication date
AU2292801A (en) 2001-07-03
WO2001045740A2 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
NO20006604L (en) Methods and transdermal compositions for pain relief
BR0113447A (en) Method of treating or preventing cancer in a human, and, pharmaceutical composition
WO2003057165A3 (en) COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
WO2004064734A3 (en) Combination therapies for the treatment of cancer
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
EP1143958B8 (en) Pharmaceutical composition and use of rnsaid for treating inflammation
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
BR9713197A (en) Means for treating prostate hypertrophy and prostate cancer
WO2003061566A3 (en) Anti-cancer combination and use thereof
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2001008677A8 (en) Methods of inhibiting osteoclast activity
IL140716A0 (en) Use of inhibitors of protein kinase c epsilon to treat pain
GB0020504D0 (en) Therapeutic method
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
BR0311146A (en) Use of tibolone and selective estrogen receptor modulator, and method and kit for treating an estrogen deficiency-related symptom in a female patient
WO2001045740A3 (en) Compositions and methods for treatment of breast cancer
AU4338501A (en) Combination chemotherapy
WO2001041747A3 (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer
ID26965A (en) MEDICINE TO PREVENT AND / OR TREAT BREAST CANCER, WHICH CONTAINS AROMATASE STEROID INHIBITORS
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
NZ501421A (en) Pharmaceutical composition containing cardenolides particularly uscharidin (uscharin) for treating excessive cell proliferation
Lissoni et al. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP